#Baricitinib in refractory #myositis? A ‘weak’ trial design comparing #Bari to #Bari Rx started 12 weeks later in
Tweet Content
#Baricitinib in refractory #myositis?
A ‘weak’ trial design comparing #Bari to #Bari Rx started 12 weeks later
in a small N =15
neat idea but NO answer
👇
looked like 👍 it worked
BUT
this is not the #RCT design that can show differences
#ACR24 @RheumNow abst#1731
@ACRheum
Show on Archive Page
On
Display in Search Results
On
PDQ
Off